Mody, R
However, this approach lacks official recommendations and has not undergone thorough clinical testing to ensure its safety and effectiveness
As GLP-1 therapies gained approval for obesity, prescribing began to diffuse beyond endocrinology into primary care, obesity medicine, and digital health platforms
20% higher D30 engagement from new features launched September 22, 2025 is based on a pre-post analysis from August 22 to October 24, 2025 of D30 engagement in key in-app behaviours (completing any Home Screen Task, tapping the Bank button to bank rewards for steps, viewing the Health Report, logging medication, or reading an article)
In fact, the omitted study was a pooled analysis of 5 RCTs 196,197,198,199,200 of 5,325 patients with obesity followed for up to 3 years, which had shown that liraglutide was no different from placebo for depressive symptoms as scored on the Patient Health Questionnaire-9, while also highlighting a small increased risk of suicidal behavior 193
R., Tong, J., Datta, R., Culler, M
